Rapport Therapeutics reported its fourth‑quarter and full‑year 2025 financial results, showing a net loss of $33.8 million for the quarter and $111.5 million for the year, up from $20.0 million and $78.3 million in the same periods a year earlier. The increase reflects higher research and development and general‑administrative expenses as the company expands its clinical pipeline.
Research and development costs rose to $30.3 million in Q4 2025, a 76 % jump from $17.2 million in Q4 2024, and to $94.8 million for the full year, up 55 % from $60.9 million in 2024. General‑administrative expenses increased to $8.3 million in the quarter and $30.3 million for the year, compared with $6.3 million and $22.1 million respectively a year earlier. The higher spend is driven by the acceleration of the Phase 3 program for RAP‑219 and additional clinical studies.
The company reported no product revenue, consistent with its status as a clinical‑stage biotechnology firm. Cash, cash equivalents and short‑term investments stood at $490.5 million at the end of the quarter, giving the company a runway that, at current burn, extends into the second half of 2029.
Management highlighted the strong clinical data for RAP‑219 in focal‑onset seizures, noting that the Phase 2a results reinforce the program’s best‑in‑class potential and support the decision to advance the candidate into Phase 3. The company also continued progress on a bipolar mania trial, a long‑acting injectable formulation, and other pipeline candidates.
While the earnings miss the consensus estimate of $-0.65 per share, the company’s guidance indicates confidence that the cash position will support operations through 2029. Analysts noted that the widening net loss is a trade‑off for accelerated development, and the company’s robust cash reserve mitigates short‑term financial pressure.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.